Literature-reported formulation composition
Component: C18 NC-TNP | mol%: 60 | Role: noncationic_lipid
sales@dcchemicals.com
C18 NC-TNP
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: Cholesterol | mol%: 40 | Role: Sterol
Literature-reported formulation composition
Component: Reported total | mol%: 100 | Role: Source values retained
Reported observation
Literature-reported mRNA expression C18 NC-TNP produced higher EGFP expression than the SM-102 benchmark in the reported cell models. C18 NC-TNP/cholesterol 60:40 mol%; EGFP mRNA 1 µg/mL; 48 h · SM-102:DSPC:cholesterol:DMG-PEG 50:10:38.5:1.5 mol% PMC article, Fig. 1 and Results; main text
Reported observation
Literature-reported Spleen biodistribution The article reports preferential spleen accumulation and a higher spleen/liver ratio than the benchmark LNP in the IV Cy5-labelled study. Cy5-labelled nanoparticle IV mouse study · SM-102 LNP PMC article, Fig. 4
Reported observation
Literature-reported Immune response OVA mRNA nanoparticles induced antigen-specific cellular and humoral responses, with durable immune-memory claims in the reported immunization schedule. OVA mRNA 1 mg/kg; SC or IV mouse immunization; day 0/7/14 schedule where stated · SM-102 benchmark and study controls PMC article, Fig. 5 and In Vivo Immune Responses
Reported observation
Literature-reported Storage stability Liquid and lyophilized formulations retained reported activity during the tested 30-day storage comparison at 4 °C. Formulated nanoparticles, 4 °C, 30 days · Fresh formulation PMC article, storage-stability section